The cumulative incidence rate of developing stroke was also lower in the SGLT2-inhibitor users than in the non-SGLT2-inhibitor in the Kaplan–Meier survival analysis (P < 0.0001; Figure 2A). Here, SLC5A2 is linked to stroke disorder.